- Adjusted Funds from Operations (AFFO) Per Share: Alexandria Real Estate reported an AFFO per share of $2.37 for the third quarter. This figure matches analyst estimates and shows an increase from $2.26 year-over-year (y/y).
- Revenue Growth: The company achieved revenue of $791.6 million, representing an 11% increase from the previous year. This figure surpasses the analyst estimate of $770.6 million.
- Earnings Per Share (EPS): EPS for the quarter was 96 cents, significantly higher than the 13 cents reported y/y and exceeding the estimate of 87 cents.
- Stock Analyst Ratings: Currently, there are 9 buy ratings, 6 hold ratings, and no sell ratings for Alexandria Real Estate.
A look at Alexandria Real Estate Equities Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
### Alexandria Real Estate Equities, Inc. acquires, manages, expands, and develops office and laboratory space properties. The company leases its properties to pharmaceutical, biotechnology, diagnostic, and personal care products companies, research institutions, and related government agencies. Properties are located in California, suburban Washington D.C., New England, the Mideast, and Southeast. ###
Based on the Smartkarma Smart Scores, Alexandria Real Estate Equities shows a solid outlook for the long term. With a strong emphasis on value and dividends, scoring 4 out of 5 in both categories, the company is seen as a reliable investment with good potential returns. However, growth and resilience scores are slightly lower at 2 and 3, respectively, indicating some room for improvement in these areas. Despite this, momentum is high at 4, suggesting positive market sentiment and potential for future growth in the company’s overall performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
